E-LIB Suche - Ergebnisse für: Uyl-De Groot, CA

1

POSA165 Medical Resource Use and Medical Costs for Radiothe..:

Chen, YH ; Molenaar, D ; Uyl-De Groot, CA..
Value in Health. 25 (2022) 1 - p. S66 , 2022

Link: https://doi.org/10.1016/..

2

POSC365 Health State Utilities of Advanced Melanoma Patient..:

Franken, M ; de Groot, S ; van Dongen, A...
Value in Health. 25 (2022) 1 - p. S243-S244 , 2022

Link: https://doi.org/10.1016/..

3

POSC366 Validity of the EQ-5D-3L and EQ-5D-5L in Advanced M..:

Franken, M ; van Dongen, A ; Leeneman, B...
Value in Health. 25 (2022) 1 - p. S244 , 2022

Link: https://doi.org/10.1016/..

4

POSC399 Treatment Effect and Costs of the Complete Therapeu..:

Holleman, MS ; Santi, I ; Huygens, S...
Value in Health. 25 (2022) 1 - p. S266-S267 , 2022

Link: https://doi.org/10.1016/..

5

P71 The Development of a Flexible and Easy to Tailor Diseas..:

de Groot, S ; Blommestein, HM ; Leeneman, B...
Value in Health. 25 (2022) 1 - p. S16 , 2022

Link: https://doi.org/10.1016/..

6

POSB361 Quality of Life in Advanced Melanoma Patients in th..:

Franken, M ; Leeneman, B ; Aarts, M.J.B....
Value in Health. 25 (2022) 1 - p. S230-S231 , 2022

Link: https://doi.org/10.1016/..

7

PMU105 - PATIENT PREFERENCES IN HEALTH TECHNOLOGY ASSESSMEN..:

Huls, SP ; Whichello, C ; van Exel, N.J...
Value in Health. 21 (2018) - p. S325 , 2018

Link: https://doi.org/10.1016/..

8

Potential Therapeutic and Economic Value of Risk-Stratified..:

Gaultney, JG ; Ng, T ; Uyl-de Groot, CA...
Value in Health. 20 (2017) 9 - p. A444-A445 , 2017

Link: https://doi.org/10.1016/..

9

How Can Middle-Income Countries Get A Valid Estimate Of Cos..:

Ansaripour, A ; Severens, JL ; Uyl-de Groot, CA.
Value in Health. 20 (2017) 9 - p. A745 , 2017

Link: https://doi.org/10.1016/..

10

Determining The Comparative Value Of Outcome-Based Money-Ba..:

Holleman, MS ; van der Linden, N ; Uyl-de Groot, CA
Value in Health. 20 (2017) 9 - p. A466 , 2017

Link: https://doi.org/10.1016/..

11

Second-Line Treatment for Steroid-Refractory Graft-Versus-H..:

Thielen, F ; Blommestein, HM ; Oosten, L...
Value in Health. 20 (2017) 9 - p. A545-A546 , 2017

Link: https://doi.org/10.1016/..

12

Cost-Utility Analysis of First-Line Gefitinib, Erlotinib an..:

Holleman, MS ; Zaim, R ; Uyl-De Groot, CA
Value in Health. 19 (2016) 7 - p. A740-A741 , 2016

Link: https://doi.org/10.1016/..

13

Real-World Evidence on Healthcare Resource use and Associat..:

Blommestein, HM ; Verelst, SG ; Zagorska, A...
Value in Health. 19 (2016) 7 - p. A751 , 2016

Link: https://doi.org/10.1016/..

14

Gefitinib, Erlotinib or Afatinib for EGFR Mutated NSCLC pat..:

Holleman, MS ; Zaim, R ; Uyl-De Groot, CA
Value in Health. 19 (2016) 7 - p. A714 , 2016

Link: https://doi.org/10.1016/..

15

Long-Term Disease Outcomes in Symptomatic Multiple Myeloma ..:

Verelst, SG ; Blommestein, HM ; De Groot, S...
Value in Health. 19 (2016) 3 - p. A170 , 2016

Link: https://doi.org/10.1016/..